GLPwatch
Papers (9189)
Page 66 of 154, ranked by citation count.
- Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice.
- Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.
- Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing Neurogenesis and reducing inflammation.
- Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers.
- Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study.
- Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice.
- Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial.
- Novel Therapeutic Approaches in Diabetes.
- Liraglutide alleviates myocardial ischemia‒reperfusion injury in diabetic mice.
- Pancreatitis during treatment with liraglutide.
- Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists.
- Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle.
- Ramadan fasting: a study of changes in glucose profiles among patients with diabetes using continuous glucose monitoring.
- [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
- The metabolic syndrome influences the response to incretin-based therapies.
- The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism.
- Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
- Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
- Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
- The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis.
- Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury.
- Exenatide Increases IL-1RA Concentration and Induces Nrf-2‒Keap-1‒Regulated Antioxidant Enzymes: Relevance to β-Cell Function.
- Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
- Oral delivery of liraglutide-loaded Poly-N-(2-hydroxypropyl) methacrylamide/chitosan nanoparticles: Preparation, characterization, and pharmacokinetics.
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-Pituitary-Adrenal Axis in Healthy Volunteers.
- Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes.
- Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice.
- Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.
- NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products.
- Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
- Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
- Permeability of exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine.
- Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis.
- Patient initiation and maintenance of GLP-1 RAs for treatment of obesity.
- Exenatide Use in the Management of Type 2 Diabetes Mellitus.
- Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
- Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.
- Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
- Adjunct therapies in treatment of type 1 diabetes.
- Liquid Chromatography-High Resolution Mass Spectrometry for Peptide Drug Quality Control.
- A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus.
- Predictors of response to liraglutide in Japanese type 2 diabetes.
- PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.
- Role of Renal Sympathetic Nerves in GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Exendin-4-Mediated Diuresis and Natriuresis in Diet-Induced Obese Rats.
- Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.
- Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
- Insulin deficiency, but not resistance, exaggerates cognitive deficits in transgenic mice expressing human amyloid and tau proteins. Reversal by Exendin-4 treatment.
- Liraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways.
- Glucagon-like peptide-1 agonist exendin-4 leads to reduction of weight and caloric intake in a rat model of hypothalamic obesity.
- Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy.
- Activation of pCREB/Nrf-2 signaling mediates re-positioning of liraglutide as hepato-protective for methotrexate -induced liver injury (MILI).
- Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.
- Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX).
- Albiglutide: a unique GLP-1 receptor agonist.
- Clinical potential of treatment with semaglutide in type 2 diabetes patients.
- Liraglutide in the treatment of obesity.
- Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.
- Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice.
- Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States.
- Mode of administration of dulaglutide: implications for treatment adherence.